CA2123211A1 - A method for assaying and treating alzheimer's disease - Google Patents

A method for assaying and treating alzheimer's disease

Info

Publication number
CA2123211A1
CA2123211A1 CA002123211A CA2123211A CA2123211A1 CA 2123211 A1 CA2123211 A1 CA 2123211A1 CA 002123211 A CA002123211 A CA 002123211A CA 2123211 A CA2123211 A CA 2123211A CA 2123211 A1 CA2123211 A1 CA 2123211A1
Authority
CA
Canada
Prior art keywords
disease
assaying
treating alzheimer
app
forms
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002123211A
Other languages
French (fr)
Other versions
CA2123211C (en
Inventor
Colin L. Masters
Ashley I. Bush
Konrad T. Beyreuther
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alterity Therapeutics Ltd
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25644152&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2123211(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Individual filed Critical Individual
Publication of CA2123211A1 publication Critical patent/CA2123211A1/en
Application granted granted Critical
Publication of CA2123211C publication Critical patent/CA2123211C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/811—Test for named disease, body condition or organ function

Abstract

The present invention relates to a method of assaying for Alzheimer's disease in a human by determining the relative abundance of one or more forms of amyloid precursor protein (APP) or the enzyme responsible for said forms in circulatory fluid and to a method for treating the disease by modulating divalent cation, trivalent cation and/or heparin interaction with APP.
CA002123211A 1991-11-12 1992-11-12 A method for assaying and treating alzheimer's disease Expired - Fee Related CA2123211C (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
AUPK943891 1991-11-12
AUPK9438 1991-11-12
AUPL337492 1992-07-08
AUPL3374 1992-07-08
PCT/AU1992/000610 WO1993010459A1 (en) 1991-11-12 1992-11-12 A method for assaying and treating alzheimer's disease

Publications (2)

Publication Number Publication Date
CA2123211A1 true CA2123211A1 (en) 1993-05-27
CA2123211C CA2123211C (en) 2008-09-16

Family

ID=25644152

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002123211A Expired - Fee Related CA2123211C (en) 1991-11-12 1992-11-12 A method for assaying and treating alzheimer's disease

Country Status (7)

Country Link
US (2) US5705401A (en)
EP (1) EP0613560B2 (en)
JP (1) JP3277211B2 (en)
AU (1) AU669493B2 (en)
CA (1) CA2123211C (en)
DE (1) DE69227380T3 (en)
WO (1) WO1993010459A1 (en)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993010459A1 (en) * 1991-11-12 1993-05-27 The University Of Melbourne A method for assaying and treating alzheimer's disease
DK1060750T3 (en) * 1993-03-29 2006-01-09 Univ Kingston Propane-1,3-disulfonic acid and its pharmaceutically acceptable salts for the treatment of amyloidosis
US20040208875A1 (en) 1995-03-15 2004-10-21 Queen's University At Kingston Method for treating amyloidosis
US6017887A (en) * 1995-01-06 2000-01-25 Sibia Neurosciences, Inc. Peptide, peptide analog and amino acid analog protease inhibitors
US5804560A (en) * 1995-01-06 1998-09-08 Sibia Neurosciences, Inc. Peptide and peptide analog protease inhibitors
US5789426A (en) * 1995-01-20 1998-08-04 Cornell Research Foundation, Inc. Method for the treatment of fibroproliferative disorders by application of inhibitors of protein hydroxylation
DE19518845A1 (en) * 1995-05-23 1996-11-28 Beiersdorf Ag Cosmetic or dermatological preparations containing phytic acid
JPH0925234A (en) * 1995-07-12 1997-01-28 Wakunaga Pharmaceut Co Ltd Improving agent for cerebropathy
WO1997009976A2 (en) * 1995-09-01 1997-03-20 Washington University Method of reducing neurotoxic injury with zinc chelators
IL115465A0 (en) * 1995-09-29 1995-12-31 Yeda Res & Dev Assay for the diagnosis of dementia
AUPN649395A0 (en) * 1995-11-10 1995-12-07 Ramsay Health Care Pty Ltd A method for diagnosing alzheimer's disease
GB9610829D0 (en) 1996-05-23 1996-07-31 Medical Res Council Screening of agents for treatment of azlheimers disease
CA2264097C (en) * 1996-08-13 2007-11-27 P.N. Gerolymatos S.A. Use of the chelating agent clioquinol for the manufacture of a pharmaceutical composition for the treatment of alzheimer's disease
EP1007048A4 (en) * 1997-03-11 2004-09-22 Gen Hospital Corp Identification of agents for use in the treatment of alzheimer's disease
US7045531B1 (en) 1997-03-11 2006-05-16 The General Hospital Corporation Composition comprising a metal chelator and a method of treating amyloidosis by administering the metal chelator
JP2001513558A (en) 1997-08-21 2001-09-04 パイ・ニュー・ゲロリュマトス・ソシエテ・アノニム How to use fanquinone to treat Alzheimer's disease
US5980914A (en) * 1997-08-22 1999-11-09 P.N. Gerolymatos S.A. Clioquinol for the treatment of Parkinson's disease
US5994323A (en) * 1997-12-31 1999-11-30 P.N. Gerolymatos S.A. Pharmaceutical compositions comprising clioquinol in combination with vitamin B12 and therapeutic and prophylactic uses thereof
US6183981B1 (en) 1998-03-05 2001-02-06 Board Of Regents, The University Of Texas System Diagnostic assay for late-onset Alzheimer's disease
US20020025944A1 (en) * 2000-04-28 2002-02-28 Bush Ashley I. Use of clioquinol for the therapy of Alzheimer's disease
US6638711B1 (en) 1999-04-29 2003-10-28 The General Hospital Corporation Methods for identifying an agent that inhibits oxygen-dependent hydrogen peroxide formation activity but does not inhibit superoxide-dependent hydrogen peroxide formation
US20050112543A1 (en) * 1998-03-11 2005-05-26 The General Hospital Corporation Method of screening for drugs useful in treating Alzheimer's disease
US6323218B1 (en) * 1998-03-11 2001-11-27 The General Hospital Corporation Agents for use in the treatment of Alzheimer's disease
EP1140090B1 (en) 1999-01-07 2004-12-22 P.N. Gerolymatos S.A. Use of phanquinone for the treatment or prevention of memory impairment
DE19909357A1 (en) * 1999-03-03 2000-09-07 Gerd Multhaup Copper agonist that binds to the APP copper binding site and / or has an inhibitory effect on the release of the amyloid-Aß peptide
US6087118A (en) * 1999-03-04 2000-07-11 Bristol-Myers Squibb Company Method for diagnosing alzheimer's disease
US7592304B2 (en) 1999-10-01 2009-09-22 Dmi Life Sciences, Inc. Metal-binding compounds and uses therefor
US6608042B2 (en) * 2000-03-28 2003-08-19 Aventis Pharma, S.A. Pharmaceutical compositions containing oligosaccharides, the novel oligosaccharides and preparation thereof
WO2002005634A2 (en) 2000-07-13 2002-01-24 University Of South Florida Transgenic animal and methods
US20020172676A1 (en) * 2001-05-16 2002-11-21 George Jackowski Method of treatment of alzheimer's disease and device therefor
DE10303974A1 (en) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid β (1-42) oligomers, process for their preparation and their use
US7517868B2 (en) * 2004-07-19 2009-04-14 Ip-6 Research Inc Phytic citrate compounds and process for preparing the same
BRPI0519243A2 (en) 2004-12-22 2009-01-06 Neurochem Int Ltd Methods and compositions for treating amyloid-related diseases
DE102005037298A1 (en) * 2005-08-08 2007-03-08 Christine Jaschek Use of four active electrolytes such as potassium, magnesium, calcium and zinc, as medicinal or food supplements for the treatment of Alzheimer's disease including other dementias
PT1954718E (en) 2005-11-30 2014-12-16 Abbvie Inc Anti-a globulomer antibodies, antigen-binding moieties thereof, corresponding hybridomas, nucleic acids, vectors, host cells, methods of producing said antibodies, compositions comprising said antibodies, uses of said antibodies and methods of using said antibodies
SG10201706600VA (en) 2005-11-30 2017-09-28 Abbvie Inc Monoclonal antibodies and uses thereof
JP5419131B2 (en) * 2005-12-12 2014-02-19 エーシー イミューン ソシエテ アノニム Β1-42 specific monoclonal antibodies with therapeutic properties
MX2008008213A (en) 2005-12-22 2008-09-03 Neurochem Int Ltd Treatment of renal disorders, diabetic nephopathy and dyslipidemias.
TWI551607B (en) * 2006-07-14 2016-10-01 Ａｃ免疫公司 Humanized antibody
FI3851447T3 (en) 2006-10-12 2023-11-15 Bellus Health Inc Methods, compounds, compositions and vehicles for delivering 3-amino-1-propanesulfonic acid
US8455626B2 (en) * 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
CL2007003793A1 (en) * 2006-12-22 2008-07-25 Genentech Inc METHOD FOR INHIBITING UNION OF DEATH RECEIVER 6 (DR6) TO THE AMILOID PRECURSOR PROTEIN (APP) THAT INCLUDES ONE OR MORE ANTAGONISTS OF DR6; USE OF SUCH ANTAGONISTS; METHOD FOR IDENTIFYING A MOLECULA OF INTEREST THAT INHIBITS THE DR6 UNION UNION
US20100311767A1 (en) * 2007-02-27 2010-12-09 Abbott Gmbh & Co. Kg Method for the treatment of amyloidoses
US8613923B2 (en) 2007-06-12 2013-12-24 Ac Immune S.A. Monoclonal antibody
TW201518320A (en) * 2007-06-12 2015-05-16 Ac Immune Sa Antibody specifically binding to beta amyloid and relevant nucleic acid molecule, expression vector, cell, composition, kit, method, and use
US8048420B2 (en) 2007-06-12 2011-11-01 Ac Immune S.A. Monoclonal antibody
RS53174B (en) * 2007-10-05 2014-06-30 Genentech Inc. Use of anti-amyloid beta antibody in ocular diseases
WO2009048538A2 (en) * 2007-10-05 2009-04-16 Genentech, Inc. Humanized antibody
CA2726118A1 (en) * 2008-06-12 2009-12-17 Anatoly Nikolaev Method for screening for compounds that inhibit neurodegeneration
US8501178B2 (en) 2008-11-25 2013-08-06 Biogen Idec Ma Inc. Use of DR6 and p75 antagonists to promote survival of cells of the nervous system
WO2011060246A2 (en) * 2009-11-12 2011-05-19 Genentech, Inc. A method of promoting dendritic spine density
MX336196B (en) 2010-04-15 2016-01-11 Abbvie Inc Amyloid-beta binding proteins.
RU2607368C2 (en) 2010-07-30 2017-01-10 Ац Иммуне С.А. Safe and functional humanized antibodies
WO2012024187A1 (en) 2010-08-14 2012-02-23 Abbott Laboratories Amyloid-beta binding proteins
WO2012027794A2 (en) * 2010-09-01 2012-03-08 The Mental Health Research Institute Of Victoria Method of treatment and agents useful for same
US20140302532A1 (en) 2011-04-12 2014-10-09 Quanterix Corporation Methods of determining a treatment protocol for and/or a prognosis of a patient's recovery from a brain injury
WO2012142666A1 (en) * 2011-04-19 2012-10-26 The Mental Health Research Institute Of Victoria Method of modulating amine oxidase activity and agents useful for same
US10709784B2 (en) * 2011-06-08 2020-07-14 Chelation Partners Incorporated Metal chelating compositions and methods for controlling the growth or activities of a living cell or organism
WO2015006453A2 (en) * 2013-07-09 2015-01-15 Mayo Foundation For Medical Education And Research Pet imaging of zinc transport
EP3039431A4 (en) * 2013-08-27 2017-05-03 CRC for Mental Health Ltd. Method of identifying biomarkers of neurological diseases and diagnosis of neurological diseases
EP3761783A4 (en) * 2018-02-26 2021-12-15 The Trustees of Columbia University in the City of New York Zinc associated treatment for and diagnosis of cachexia

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4281061A (en) * 1979-07-27 1981-07-28 Syva Company Double antibody for enhanced sensitivity in immunoassay
US4419365A (en) * 1981-12-21 1983-12-06 Ciba-Geigy Corporation Method of treating Alzheimer's disease
US4847082A (en) * 1987-01-21 1989-07-11 Robert Sabin Method of treatment of Alzheimer's disease using phytic acid
US4837219A (en) * 1987-11-05 1989-06-06 Jeffrey Hutterer Medication for Alzheimer's disease
US4837164A (en) * 1988-04-27 1989-06-06 Bionix Corporation Methods for diagonosing, monitoring and controlling the onset and progression of certain dementias and impeding memory loss or improving impairment of memory
US5234814A (en) * 1989-06-01 1993-08-10 Du Pont Merck Pharmaceutical Company Diagnostic assay for alzheimer's disease
JPH05507470A (en) * 1990-04-12 1993-10-28 アクゾ・エヌ・ヴエー Antigen CTAA28A32 recognized by MCA28A32
CA2079880A1 (en) * 1990-04-24 1991-10-25 William E. Van Nostrand Purification, detection and methods of use of protease nexin-2
AU8215391A (en) * 1990-06-29 1992-01-23 Case Western Reserve University Diagnostic and prognostic methods based on soluble derivatives of the beta amyloid protein precursor
WO1992003542A1 (en) * 1990-08-17 1992-03-05 Boston University PROTEASES CAUSING ABNORMAL DEGRADATION OF AMYLOID β-PROTEIN PRECURSOR
JPH04126095A (en) * 1990-09-14 1992-04-27 Asahi Chem Ind Co Ltd New monoclonal antibody and hybridoma producing the same
ATE286971T1 (en) * 1991-01-21 2005-01-15 Elan Pharm Inc TEST AND MODEL FOR ALZHEIMERS DISEASE
JPH04252956A (en) * 1991-01-29 1992-09-08 Asahi Chem Ind Co Ltd Measuring method, reagent and kit for protein
JPH04252955A (en) * 1991-01-29 1992-09-08 Asahi Chem Ind Co Ltd Measuring method, reagent and kit for protein
JPH04252954A (en) * 1991-01-29 1992-09-08 Asahi Chem Ind Co Ltd Measuring method, reagent and kit for protein
WO1993010459A1 (en) * 1991-11-12 1993-05-27 The University Of Melbourne A method for assaying and treating alzheimer's disease
TW327194B (en) * 1992-05-01 1998-02-21 American Cyanamid Co Novel amyloid precursor proteins and methods of using same

Also Published As

Publication number Publication date
JPH07503316A (en) 1995-04-06
WO1993010459A1 (en) 1993-05-27
US20040265847A1 (en) 2004-12-30
EP0613560B1 (en) 1998-10-21
AU2926392A (en) 1993-06-15
US5705401A (en) 1998-01-06
AU669493B2 (en) 1996-06-13
DE69227380D1 (en) 1998-11-26
JP3277211B2 (en) 2002-04-22
EP0613560A1 (en) 1994-09-07
DE69227380T2 (en) 1999-04-08
DE69227380T3 (en) 2007-01-11
CA2123211C (en) 2008-09-16
EP0613560A4 (en) 1995-05-17
EP0613560B2 (en) 2006-06-21

Similar Documents

Publication Publication Date Title
CA2123211A1 (en) A method for assaying and treating alzheimer's disease
DE68903516D1 (en) AGENT FOR REDUCING BLOOD PRESSURE.
DE69002246T2 (en) Coating, glossy or polishing disc.
DE69003970T2 (en) Blood preservation system.
DE59005543D1 (en) ROLLER FOR PRESSURE TREATING TRACKS.
CA2212058A1 (en) Preparation and use of a specific gaba-a.alpha.5 receptor ligand for treatment of alzheimer's disease
DE3777417D1 (en) METHOD FOR THE CRYCON PRESERVATION OF HEART VALVES.
ZA967948B (en) Craps qualified by blackjack.
DE3775222D1 (en) ELECTRONICALLY CONTROLLED PRESSURE BRAKE SYSTEM.
DE69023793T2 (en) Pressure control valve.
DE69022355D1 (en) Vehicle brake fluid pressure control method.
DE288411T1 (en) VARIABLE PRESSURE CONTROL VALVE.
DE58904713D1 (en) USE OF ZINC OR IRON HYDROXIDE FOR ADJUVING ANTIQUE SOLUTIONS AND IN THIS WAY ADJUVED ANTIQUE SOLUTIONS.
IT8721384A0 (en) PRESSURE REGULATING VALVE.
DE3769027D1 (en) SOLENOID PRESSURE CONTROL VALVES.
IT8721896A0 (en) SMALL UNVIOLABLE SOLENOID VALVE.
DK162999C (en) IMIDAZOQUINAZOLINE COMPOUND AND PROCEDURE FOR PREPARING THEREOF
DE3862800D1 (en) PRESSURE CONTROL VALVE.
AU569354B2 (en) (-)-1,7-diphenyl-3-methylaza-7-cyano-8-methylnonane
FR2651341B1 (en) FLOW OR PRESSURE REGULATOR.
GB2197405B (en) Brake control valve.
EP0761686A3 (en) Anticoagulant factor Va derivatives
AU8373282A (en) 2-diethylamino-ethyl 3-(naphthyl)-2-tetrahydrofuryl- propionate citrate
FR2718254B1 (en) Glasses, especially for sight or sunglasses, and frame relating thereto.
IT1238207B (en) VITAMINIZED PREPARATION CONTAINING THE ENZYME LYZYZE USABLE IN ZOOTECHNICS AND PROCEDURE FOR ITS PRODUCTION.

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed